In summary, this study systematically reveals the pivotal role of the CD2–CD58 signaling axis in BCBM, demonstrating that CD2 downregulation impairs CTL function, disrupts immune recognition, and promotes tumor metabolic reprogramming, ultimately facilitating tumor progression and microenvironmental remodeling. This evidence concerns the gene CD58 and neoplasm.